Between November 2020 to July 2021, the CLSA COVID-19 Antibody Study (also known as the CLSA COVID-19 Seroprevalence Study) collected and analyzed blood samples from CLSA participants in 10 provinces to test for the presence of antibodies that indicates infection due to the SARS-CoV-2 virus.

The CLSA COVID-19 Antibody study was funded and conducted in partnership with the Government of Canada’s COVID-19 Immunity Task Force. The mandate of this task force is to describe how widespread the coronavirus infection is in Canada.

Individual results from the CLSA COVID-19 Antibody Study have been sent to all participants. Additional information about SARS-CoV-2 antibody tests can be found here.

A summary of findings from the CLSA COVID-19 Antibody Study is available here.